Unravelling the landscape of Cannabis craving pharmacological treatments: a PRISMA-guided review of evidence

References

• Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., Booth, J., & McGregor, I. S. (2014). Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry, 71(3), 281–291. doi: 10.1001/jamapsychiatry.2013.3947.
   PubMed Web of Science ®Google Scholar
• Bahji, A., Meyyappan, A. C., Hawken, E. R., & Tibbo, P. G. (2021). Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis. The International Journal on Drug Policy, 97, 103295. doi: 10.1016/j.drugpo.2021.103295.
   PubMed Web of Science ®Google Scholar
• Brezing, C. A., & Levin, F. R. (2018). The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 43(1), 173–194. doi: 10.1038/npp.2017.212.
   PubMed Web of Science ®Google Scholar
• Bonnet, U., & Preuss, U. W. (2017). The cannabis withdrawal syndrome: Current insights. Substance Abuse and Rehabilitation, 8, 9–37. doi: 10.2147/SAR.S109576.
   PubMed Web of Science ®Google Scholar
• Cooper, Z. D., Foltin, R. W., Hart, C. L., Vosburg, S. K., Comer, S. D., & Haney, M. (2013). A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addiction Biology, 18(6), 993–1002. doi: 10.1111/j.1369-1600.2012.00461.x.
   PubMed Web of Science ®Google Scholar
• Filbey, F. M., & DeWitt, S. J. (2012). Cannabis cue-elicited craving and the reward neurocircuitry. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 38(1), 30–35. doi: 10.1016/j.pnpbp.2011.11.001.
   PubMed Web of Science ®Google Scholar
• Gorey, C., Kroon, E., Runia, N., Bornovalova, M., & Cousijn, J. (2023). Direct Effects of Cannabis Intoxication on Motivations for Softer and Harder Drug Use: An Experimental Approach to the Gateway Hypothesis. Cannabis and Cannabinoid Research. doi: 10.1089/can.2022.0157.
   PubMedGoogle Scholar
• Gray, K. M., Sonne, S. C., McClure, E. A., Ghitza, U. E., Matthews, A. G., McRae-Clark, A. L., Carroll, K. M., Potter, J. S., Wiest, K., Mooney, L. J., Hasson, A., Walsh, S. L., Lofwall, M. R., Babalonis, S., Lindblad, R. W., Sparenborg, S., Wahle, A., King, J. S., Baker, N. L., Tomko, R. L., … Levin, F. R. (2017). A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence, 177, 249-257. doi: 10.1016/j.drugalcdep.2017.04.020.
   PubMed Web of Science ®Google Scholar
• Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., Jung, J., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., & Grant, B. F. (2015). Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry, 72(12), 1235–1242. doi: 10.1001/jamapsychiatry.2015.1858.
   PubMed Web of Science ®Google Scholar
• Haney, M., Hart, C. L., Vosburg, S. K., Comer, S. D., Reed, S. C., & Foltin, R. W. (2008). Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology, 197(1), 157–168. doi: 10.1007/s00213-007-1020-8.
   PubMed Web of Science ®Google Scholar
• Henry, E. A., Kaye, J. T., Bryan, A. D., Hutchison, K. E., & Ito, T. A. (2014). Cannabis cue reactivity and craving among never, infrequent and heavy cannabis users. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 39(5), 1214–1221. doi: 10.1038/npp.2013.324.
   PubMed Web of Science ®Google Scholar
• Herrmann, E. S., Weerts, E. M., & Vandrey, R. (2015). Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Experimental and Clinical Psychopharmacology, 23(6), 415–421. doi: 10.1037/pha0000053.
   PubMed Web of Science ®Google Scholar
• Herrmann, E. S., Cooper, Z. D., Bedi, G., Ramesh, D., Reed, S. C., Comer, S. D., Foltin, R. W., & Haney, M. (2019). Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. Addiction Biology, 24(4), 765–776. doi: 10.1111/adb.12664.
   PubMed Web of Science ®Google Scholar
• Hill, K. P., Palastro, M. D., Gruber, S. A., Fitzmaurice, G. M., Greenfield, S. F., Lukas, S. E., & Weiss, R. D. (2017). Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. American Journal on Addictions, 26(8), 795–801. doi: 10.1111/ajad.12622.
   PubMed Web of Science ®Google Scholar
• Holst, M., Mathai, D. S., Patel, M. M., Rodgman, C., Keller, J., Hussain, M. Z., De La Garza, R., 2nd, Kosten, T. R., & Verrico, C. D. (2019). Use of guanfacine for cannabis use disorder and related symptomology. American Journal on Addictions, 28(6), 455–464. doi: 10.1111/ajad.12959.
   PubMed Web of Science ®Google Scholar
• Janakiraman, R., Gowin, J. L., Sloan, M. E., Schwandt, M. L., Diazgranados, N., Ramchandani, V. A., & Kwako, L. E. (2020). History of suicidality and alcohol craving trajectories during inpatient treatment for alcohol use disorder. Drug and Alcohol Dependence, 209, 107918. doi: 10.1016/j.drugalcdep.2020.107918.
   PubMed Web of Science ®Google Scholar
• Kondo, K., Morasco, B. J., Nugent, S., Ayers, C., O’Neil, M. E., Freeman, M., Paynter, R., & Kansagara, D. (2019). Pharmacotherapy for the treatment of cannabis use disorder: A systematic review. Department of Veterans Affairs.
   Google Scholar
• Lassi, D. L. S., Malbergier, A., Negrão, A. B., Florio, L., De Aquino, J. P., & Castaldelli-Maia, J. M. (2022). Pharmacological treatments for cocaine craving: What is the way forward? A systematic review. Brain Sciences, 12(11), 1546. doi: 10.3390/brainsci12111546.
   PubMed Web of Science ®Google Scholar
• Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011). Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 116(1–3), 142–150. doi: 10.1016/j.drugalcdep.2010.12.010.
   PubMed Web of Science ®Google Scholar
• Levin, F. R., Mariani, J. J., Pavlicova, M., Brooks, D., Glass, A., Mahony, A., Nunes, E. V., Bisaga, A., Dakwar, E., Carpenter, K. M., Sullivan, M. A., & Choi, J. C. (2016). Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 159, 53–60. doi: 10.1016/j.drugalcdep.2015.11.025.
   PubMed Web of Science ®Google Scholar
• Li, J., Weidacker, K., Mandali, A., Zhang, Y., Whiteford, S., Ren, Q., Zhou, Z., Zhou, H., Jiang, H., Du, J., Zhang, C., Sun, B., & Voon, V. (2021). Impulsivity and craving in subjects with opioid use disorder on methadone maintenance treatment. Drug and Alcohol Dependence, 219, 108483. doi: 10.1016/j.drugalcdep.2020.108483.
   PubMed Web of Science ®Google Scholar
• Lintzeris, N., Bhardwaj, A., Mills, L., Dunlop, A., Copeland, J., McGregor, I., Bruno, R., Gugusheff, J., Phung, N., Montebello, M., Chan, T., Kirby, A., Hall, M., Jefferies, M., Luksza, J., Shanahan, M., Kevin, R., & Allsop, D, Agonist Replacement for Cannabis Dependence (ARCD) study group. (2019). Nabiximols for the treatment of cannabis dependence: A randomized clinical trial. JAMA Internal Medicine, 179(9), 1242–1253. doi: 10.1001/jamainternmed.2019.1993.
   PubMed Web of Science ®Google Scholar
• Macatee, R. J., Carr, M., Afshar, K., & Preston, T. J. (2021). Development and validation of a cannabis cue stimulus set. Addictive Behaviors, 112, 106643. doi: 10.1016/j.addbeh.2020.106643.
   PubMed Web of Science ®Google Scholar
• McRae-Clark, A. L., Carter, R. E., Killeen, T. K., Carpenter, M. J., Wahlquist, A. E., Simpson, S. A., & Brady, K. T. (2009). A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug and Alcohol Dependence, 105(1–2), 132–138. doi: 10.1016/j.drugalcdep.2009.06.022.
   PubMed Web of Science ®Google Scholar
• McRae-Clark, A. L., Carter, R. E., Killeen, T. K., Carpenter, M. J., White, K. G., & Brady, K. T. (2010). A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. American Journal on Addictions, 19(6), 481–489. doi: 10.1111/j.1521-0391.2010.00076.x.
   PubMed Web of Science ®Google Scholar
• McRae-Clark, A. L., Baker, N. L., Maria, M. M., & Brady, K. T. (2013). Effect of oxytocin on craving and stress response in marijuana-dependent individuals: A pilot study. Psychopharmacology, 228(4), 623–631. doi: 10.1007/s00213-013-3062-4.
   PubMed Web of Science ®Google Scholar
• McRae-Clark, A. L., Baker, N. L., Gray, K. M., Killeen, T. K., Wagner, A. M., Brady, K. T., DeVane, C. L., & Norton, J. (2015). Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug and Alcohol Dependence, 156, 29–37. doi: 10.1016/j.drugalcdep.2015.08.013.
   PubMed Web of Science ®Google Scholar
• McRae-Clark, A. L., Baker, N. L., Gray, K. M., Killeen, T., Hartwell, K. J., & Simonian, S. J. (2016). Vilazodone for cannabis dependence: A randomized, controlled pilot trial. American Journal on Addictions, 25(1), 69–75. doi: 10.1111/ajad.12324.
   PubMed Web of Science ®Google Scholar
• Nardone, R., Sebastianelli, L., Versace, V., Ferrazzoli, D., Brigo, F., Schwenker, K., Saltuari, L., & Trinka, E. (2022). TMS for the functional evaluation of cannabis effects and for treatment of cannabis addiction: A review. Psychiatry Research, 310, 114431. doi: 10.1016/j.psychres.2022.114431.
   PubMed Web of Science ®Google Scholar
• Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019). Pharmacotherapies for cannabis dependence. Cochrane Database of Systematic Reviews, 1(1), CD008940. doi: 10.1002/14651858.CD008940.pub3.
   PubMedGoogle Scholar
• Peraza, N., Smit, T., Garey, L., Manning, K., Buckner, J. D., & Zvolensky, M. J. (2019). Distress tolerance and cessation-related cannabis processes: The role of cannabis use coping motives. Addictive Behaviors, 90, 164–170. doi: 10.1016/j.addbeh.2018.10.047.
   PubMed Web of Science ®Google Scholar
• Penetar, D. M., Looby, A. R., Ryan, E. T., Maywalt, M. A., & Lukas, S. E. (2012). Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study. Substance Abuse: Research and Treatment, 6, 63–71. doi: 10.4137/SART.S9706.
   PubMedGoogle Scholar
• Roten, A. T., Baker, N. L., & Gray, K. M. (2013). Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addictive Behaviors, 38(3), 1788–1791. doi: 10.1016/j.addbeh.2012.11.003.
   PubMed Web of Science ®Google Scholar
• Sherman, B. J., & McRae-Clark, A. L. (2016). Treatment of cannabis use disorder: Current science and future outlook. Pharmacotherapy, 36(5), 511–535. doi: 10.1002/phar.1747.
   PubMed Web of Science ®Google Scholar
• Sherman, B. J., Caruso, M. A., & McRae-Clark, A. L. (2019). Exogenous progesterone for cannabis withdrawal in women: Feasibility trial of a novel multimodal methodology. Pharmacology, Biochemistry, and Behavior, 179, 22–26. doi: 10.1016/j.pbb.2019.01.008.
   PubMed Web of Science ®Google Scholar
• Spanagel, R. (2020). Cannabinoids and the endocannabinoid system in reward processing and addiction: From mechanisms to interventions. Dialogues in Clinical Neuroscience, 22(3), 241–250. doi: 10.31887/DCNS.2020.22.3/rspanagel.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality.
   Google Scholar
• Treloar Padovano, H., & Miranda, R.Jr. (2018). Using Ecological momentary assessment to identify mechanisms of change: An application from a pharmacotherapy trial with adolescent cannabis users. Journal of Studies on Alcohol and Drugs, 79(2), 190–198. doi: 10.15288/jsad.2018.79.190.
   PubMed Web of Science ®Google Scholar
• Trigo, J. M., Lagzdins, D., Rehm, J., Selby, P., Gamaleddin, I., Fischer, B., Barnes, A. J., Huestis, M. A., & Le Foll, B. (2016). Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug and Alcohol Dependence, 161, 298–306. doi: 10.1016/j.drugalcdep.2016.02.020.
   PubMed Web of Science ®Google Scholar
• Trigo, J. M., Soliman, A., Quilty, L. C., Fischer, B., Rehm, J., Selby, P., Barnes, A. J., Huestis, M. A., George, T. P., Streiner, D. L., Staios, G., & Le Foll, B. (2018). Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PloS One, 13(1), e0190768. doi: 10.1371/journal.pone.0190768.
   PubMed Web of Science ®Google Scholar
• Wesley, M. J., Westgate, P. M., Stoops, W. W., Kelly, T. H., Hays, L. R., & Lile, J. A. (2018). Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users. Experimental and clinical psychopharmacology, 177 (3) 310-319. https://doi.org/10.1037/pha0000180
   Google Scholar